The Hypercoagulable State of Malignancy: Pathogenesis and Current Debate

This publication has 97 references indexed in Scilit:

• Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer
  The Lancet, 1994
• The hypercoagulable state in cancer patients
  Blood Coagulation & Fibrinolysis, 1994
• Hemostatic alterations in cancer patients
  Cancer and Metastasis Reviews, 1992
• Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynecological malignancies
  International Journal of Cancer, 1990
• A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
  New England Journal of Medicine, 1989
• The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer
  New England Journal of Medicine, 1988
• Expression of Plasminogen Activator as a Marker of Stimulation in Tumor-Associated Macrophages
  Pathophysiology of Haemostasis and Thrombosis, 1988
• Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone
  Science, 1983
• Cultured human endothelial cells generate tissue factor in response to endotoxin.
  Journal of Clinical Investigation, 1983
• Diagnostic Value of Fibrinopeptide A and Beta‐Thromboglobulin in Acute Deep Venous Thrombosis and Pulmonary Embolism
  Acta Medica Scandinavica, 1982